Increasing interest in psychedelic and related drugs as potential therapies for a wide spectrum of difficult-to-treat conditions, that extend beyond neuropsychiatric disorders, provided the impetus for this themed issue. This collection of reviews and original articles includes the mechanistic basis of how these drugs act, the current status of preclinical research and progress in clinical...
Psychedelic-assisted therapies (PATs) are emerging as novel combination treatments for selected stress- and trauma-related psychiatric conditions, particularly in cases where existing pharmacologic and psychotherapeutic approaches have provided limited benefit. Although current mechanistic models emphasize neuroplasticity, large-scale network changes, and modulation of neurotransmitter systems,...
This Viewpoint discusses the executive order supporting the development and approval of psychedelic drugs and outlines issues surrounding their ethical and evidence-based integration into clinical care.
Over the past two decades, ketamine has emerged as a rapid-acting antidepressant, especially among patients with treatment-resistant depression. As an N-methyl-d-aspartate glutamate receptor antagonist, ketamine has reshaped the understanding of the underlying neurobiological mechanisms of depression treatment. Ketamine induces a transient state of enhanced neuroplasticity and likely...
The psychedelic renaissance has now lasted longer than the first wave of medical research in the 1950s and 60 s. Despite growing scientific and cultural interest, fundamental questions remain regarding the nature of subjective experience and its role in therapeutic outcomes. This article revisits a neglected yet significant aspect of psychedelic phenomenology: birth—or rebirth—experiences....
The revival of psychedelic medicalization is often narrated as a story of scientific legitimacy and neurotherapeutic promise, yet the unusual sensitivity of psychedelics to environmental conditions has encouraged research on music, therapy, setting, and other contextual factors. Treating setting and context as the building blocks of felt atmospheres, this article examines how regulation...
Many people with cancer (PWC) continue to experience persistent biopsychosocial and existential challenges across the cancer care continuum. Symptoms such as anxiety, depression, cancer-related fatigue and pain, sleep disturbance, fear of cancer recurrence, cognitive impairment, and reduced quality of life remain highly prevalent during and after treatment, underscoring the need for...
Patients with treatment‐resistant depression who received psilocybin‐assisted psychotherapy showed clinically meaningful improvement in depressive symptoms relative to placebo, a Phase 2b trial has found. However, the study did not show a significant effect on the primary outcome of treatment response 6 weeks after the first of two doses of psilocybin. Study results were published online March...
Treatment-resistant depression (TRD) represents an unmet challenge, accounting for disproportionate morbidity, disability, and healthcare burden in depression. Limitations of monoaminergic antidepressants have prompted a conceptual shift toward models emphasizing impaired neuroplasticity, synaptic dysfunction, and network dysregulation. This expert review synthesizes preclinical, translational,...
Psychedelic and substance-assisted therapies are attracting renewed scientific, clinical, and public interest as potential interventions for mental health disorders, particularly treatment-resistant depression, post-traumatic stress disorder, and substance use disorders. However, as the field moves from early efficacy trials toward clinical implementation, major questions remain regarding...